Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

NMR vs MFG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MFG Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–3 Matrix Metrics)

MFG Overall Winner 6-Pillar Tally: NMR 1 – 4 MFG (1 Tie) Matrix Metrics: NMR 3 – 6 MFG

As of Nov 17, 2026, Mizuho Financial Group, Inc. (MFG) is the stronger overall head-to-head candidate over Nomura Holdings, Inc (NMR) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NMR carries a Unified Composite Score of 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin), whereas MFG carries 55.7/100 (HOLD) at $9.79 (15.1x Forward P/E, 40.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NMR vs MFG
NMR NYSE
Nomura Holdings, Inc
Security Brokers, Dealers & Flotation Companies
$9.34
-1.74% 1D
Market Cap $28.3B
TTM Revenue $14.9B
Forward P/E 12.7x
Beta / 30D Vol 1.03β · 29% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 47.0 Fund 49.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.5 · SMA20: $9.40 · SMA50: $9.68
MFG NYSE Head-to-Head Winner
Mizuho Financial Group, Inc. American Depositary Shares (Each representing one-fifth of an Ordinary Share)
National Commercial Banks
$9.79
-4.44% 1D
Market Cap $124.8B
TTM Revenue $31.2B
Forward P/E 15.1x
Beta / 30D Vol 1.32β · 38% Vol
Unified Composite Score
55.7 / 100 HOLD
Tech 45.0 Fund 47.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.3 · SMA20: $9.80 · SMA50: $10.40

6-Pillar Scorecard Institutional Category Breakdown (NMR 1 – 4 MFG)

Columns: Metric · NMR · MFG
1. Valuation Multiples NMR
Forward P/E 12.7x 15.1x
Trailing P/E 11.2x 13.6x
PEG Ratio 0.81x 1.13x
EV / Revenue 1.9x 4.0x
2. Growth & Scale MFG
Revenue Growth (YoY) +17.9% +17.8%
Earnings Growth (YoY) +13.6% +21.7%
TTM Revenue (USD) $14.9B $31.2B
Market Cap $28.3B $124.8B
3. Profitability & Quality MFG
Gross Margin 77.4% 100.0%
Operating Margin 25.1% 40.0%
Net Profit Margin 17.1% 29.4%
Return on Equity (ROE) 11.5% 13.1%
4. Balance Sheet & Cash Flow MFG
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $8.17 Book/Sh · 11.5% ROE $5.86 Book/Sh · 13.1% ROE
Dividend Yield 3.34% 1.78%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 30.7% (<1st %ile) 23.1% (50th %ile)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat MFG
OpEx & R&D Intensity 52.3% of Rev ($7.77B) 60.0% of Rev ($18.7B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat High-Margin Pricing Power Moat
Supply-Chain Role Capital Markets Operator Banks - Regional Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NMR (3) vs MFG (6)
Institutional Metric NMR MFG Criterion Row Edge
Market Capitalization
Scale
$28.3B $124.8B Larger Scale MFG
Trailing P/E Ratio
Valuation
11.2x 13.6x Lower Multiple NMR
Forward P/E Ratio
Valuation
12.7x 15.1x Lower Multiple NMR
Revenue Growth (YoY)
Growth
+17.9% +17.8% Higher Growth Tie
Operating Margin (TTM)
Profitability
25.1% 40.0% Higher Margin MFG
Net Profit Margin
Profitability
17.1% 29.4% Higher Margin MFG
Return on Equity (ROE)
Capital Efficiency
11.5% 13.1% Higher ROE MFG
52-Week Range Position
Momentum
60% ($7–$11) 66% ($6–$11) Stronger Trend MFG
Beta / 30D Volatility
Risk Regime
1.03β · 29% Vol 1.32β · 38% Vol Lower Realized Risk NMR
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 55.7 / 100 (HOLD) Higher Composite MFG
Trailing 12M Revenue (USD)
Operating Scale
$14.9B $31.2B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
77.4% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.81x PEG · 1.9x EV/Rev 1.13x PEG · 4.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($8.17 Book/Sh · 11.5% ROE) N/A ($5.86 Book/Sh · 13.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NMR +5.09 pp
NMR: +2.36% · MFG: -2.73%
3M Horizon NMR +1.56 pp
NMR: -1.84% · MFG: -3.4%
6M Horizon NMR +3.97 pp
NMR: +16.69% · MFG: +12.72%
1Y Horizon MFG +12.62 pp
NMR: +26.32% · MFG: +38.94%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NMR vs MFG. Trailing 12-month operating profitability (NMR 25.1% vs MFG 40.0%) and valuation multiples (NMR 12.7x vs MFG 15.1x Forward P/E) are benchmarked directly in Pillar 4 below.

NMR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$14.9B
Gross Margin77.4%
Op. Margin25.1%
ROE / Fwd P/E11.5% · 12.7x
MFG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$31.2B
Gross Margin100.0%
Op. Margin40.0%
ROE / Fwd P/E13.1% · 15.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NMR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 30.7%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MFG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 23.1%
IV Percentile 50th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MFG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NMR Moat Profile Scale & Operating Efficiency Moat
Capital Markets Operator
Competes within the Capital Markets value chain with $28.3B market capitalization and 25.1% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($7.77B)
90D Engineering Disclosures 0 Published
MFG Moat Profile High-Margin Pricing Power Moat
Banks - Regional Operator
Competes within the Banks - Regional value chain with $124.8B market capitalization and 40.0% operating margin.
OpEx & R&D Reinvestment 60.0% of Rev ($18.7B)
90D Engineering Disclosures 0 Published

Investor FAQ NMR vs MFG Key Questions & Quantitative Answers

As of Nov 17, 2026, Mizuho Financial Group, Inc. (MFG) is the stronger overall head-to-head candidate over Nomura Holdings, Inc (NMR) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NMR carries a Unified Composite Score of 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin), whereas MFG carries 55.7/100 (HOLD) at $9.79 (15.1x Forward P/E, 40.0% operating margin). Technically, NMR sits in a Neutral phase (RSI 45.5, UNCLASSIFIED options structure) and MFG sits in a Neutral phase (RSI 45.3, UNCLASSIFIED options structure).

MFG leads the Growth & Scale pillar: NMR posts +17.9% YoY revenue growth and +13.6% YoY earnings growth on $14.9B TTM revenue (77.4% gross margin, 25.1% operating margin), compared with MFG at +17.8% YoY revenue growth and +21.7% YoY earnings growth on $31.2B TTM revenue (100.0% gross margin, 40.0% operating margin). On trailing 12-month operating scale, NMR generates $14.9B in USD-normalized revenue versus $31.2B for MFG. In operating R&D and SG&A reinvestment, NMR deploys 52.3% of Rev ($7.77B) (0 90-day corporate R&D disclosures) versus 60.0% of Rev ($18.7B) (0 disclosures) for MFG.

NMR screens cheaper on headline valuation multiples. NMR trades at 12.7x Forward P/E, 11.2x Trailing P/E, 0.81x PEG, and 1.9x EV/Revenue (unreported cash flow margin), whereas MFG trades at 15.1x Forward P/E, 13.6x Trailing P/E, 1.13x PEG, and 4.0x EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMR (11.5% ROE) versus MFG (13.1% ROE) capital efficiency.

In options market volatility and institutional positioning, NMR carries 30.7% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.03β · 29% Vol realized risk). By comparison, MFG carries 23.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.32β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Mizuho Financial Group, Inc. American Depositary Shares (Each representing one-fifth of an Ordinary Share) (MFG) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.